GuruFocus.com via Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
1 hour ago
Austin Daily Herald
Small Business - Austin Daily Herald | Austin Daily Herald
3 hours ago
Reuters
Regeneron misses profit estimates on weaker Eylea and Dupixent sales
Reuters via Yahoo Finance
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Zacks via Yahoo Finance
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
2 days ago
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
WSAU Wausau
AbbVie’s skin disease drug found to be more effective than Regeneron’s Dupixent in study
7 days ago
Investing.com
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By Benzinga
Motley Fool via Yahoo Finance
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals (NASDAQ:REGN)